GUILLERMO
LÓPEZ VIVANCO
Investigador hasta 2022
Hospital Regional Universitario de Málaga
Málaga, EspañaPublicaciones en colaboración con investigadores/as de Hospital Regional Universitario de Málaga (10)
2022
-
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
Journal of Clinical Oncology, Vol. 71
-
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
Translational Lung Cancer Research, Vol. 11, Núm. 1, pp. 53-63
2021
-
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8
-
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
Clinical Cancer Research, Vol. 27, Núm. 21, pp. 5878-5890
2020
-
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422
2019
-
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer
Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310
2014
-
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies
Annals of Oncology, Vol. 25, Núm. 11, pp. 2147-2155
2012
2010
-
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients
Lung Cancer, Vol. 68, Núm. 3, pp. 491-497
2006
-
The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer
Revue des Maladies Respiratoires, Vol. 23, Núm. 5 C3